Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing
Three statutes across five years, discharged on one date. Evernorth says only the source of criteria changes, not the review process itself.
The Brief
A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing.
The approach came in 2017 as Philips prepared to close the plant. A site closure is a knowledge event before it is a cost event.
DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes
DOJ did not settle with a health plan. It settled with the in-home vendor that supplied the codes, and named the risk-share contract as the incentive.
Teva Faces New Probe in Turkey Over Conduct Flagged by EU
Not a new theory of harm. It is the European Commission’s Copaxone decision run a second time, with two of the same corporate entities named.
Japan Approved Orladeyo for Under-Twelves in an Open-Label Interim Analysis of 29 Children
The molecule has been approved in Japan since 2021. What is new is a formulation a two-year-old can swallow, and that is the commercial move.
A Dual MYC and GSPT1 Degrader Extended Survival by Over 300% in One Preclinical Model
The loop is the discovery, not the degrader. If GSPT1 supports MYC translation, a GSPT1-only degrader should permit MYC to recover.
China Will Pay One Price for 158 Conditions, Whatever the Hospital
Same disease, same payment across tiers. Of 31 DRG categories, 27 are internal medicine, where drug cost rather than theatre time drives the case.
France Funded Two Cancer Drugs the Same Week. One Was Rated Therapeutic Progress, One Was Not.
Listing is granted by indication, not by licence. Columvi is funded for one situation and refused for the rest of its authorisation.
Avulux Won a De Novo and Created the Category Its Competitors Will File Into
Going first through a De Novo builds the road behind you. Avulux owns the claim today and has created the category rivals will file 510(k)s into.
ASCO’s First ctDNA Guideline Found Few Instances of Clinical Utility. Residual Disease Got No Recommendation at All.
Most of the guideline concerns where ctDNA should not be used. The application carrying the largest commercial expectations got no recommendation.